EP0866705A4 - Fibrinogen receptor antagonists - Google Patents

Fibrinogen receptor antagonists

Info

Publication number
EP0866705A4
EP0866705A4 EP96936505A EP96936505A EP0866705A4 EP 0866705 A4 EP0866705 A4 EP 0866705A4 EP 96936505 A EP96936505 A EP 96936505A EP 96936505 A EP96936505 A EP 96936505A EP 0866705 A4 EP0866705 A4 EP 0866705A4
Authority
EP
European Patent Office
Prior art keywords
receptor antagonists
fibrinogen receptor
fibrinogen
antagonists
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96936505A
Other languages
German (de)
French (fr)
Other versions
EP0866705A1 (en
Inventor
Ben C Askew
George D Hartman
Mark E Duggan
Steven D Young
John H Hutchinson
John S Wai
Melissa S Egbertson
Laura M Vassallo
Laura A Libby
Nathan C Ihle
Amy E Krause
Wasyl Halczenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603371.7A external-priority patent/GB9603371D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0866705A1 publication Critical patent/EP0866705A1/en
Publication of EP0866705A4 publication Critical patent/EP0866705A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP96936505A 1995-10-19 1996-10-15 Fibrinogen receptor antagonists Withdrawn EP0866705A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US560295P 1995-10-19 1995-10-19
US5602P 1995-10-19
GB9603371 1996-02-16
GBGB9603371.7A GB9603371D0 (en) 1996-02-16 1996-02-16 Fibrinogen receptor antagonists
PCT/US1996/016491 WO1997014417A1 (en) 1995-10-19 1996-10-15 Fibrinogen receptor antagonists

Publications (2)

Publication Number Publication Date
EP0866705A1 EP0866705A1 (en) 1998-09-30
EP0866705A4 true EP0866705A4 (en) 1999-03-03

Family

ID=26308744

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96936505A Withdrawn EP0866705A4 (en) 1995-10-19 1996-10-15 Fibrinogen receptor antagonists

Country Status (5)

Country Link
EP (1) EP0866705A4 (en)
JP (1) JPH11513686A (en)
AU (1) AU713247B2 (en)
CA (1) CA2234967A1 (en)
WO (1) WO1997014417A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5889023A (en) * 1996-05-10 1999-03-30 Merck & Co., Inc. Fibrinogen receptor antagonist
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
WO1998046628A1 (en) * 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
WO1998046627A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
AU6896298A (en) 1997-04-14 1998-11-11 Cor Therapeutics, Inc. Selective factor xa inhibitors
WO1998046591A1 (en) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. SELECTIVE FACTOR Xa INHIBITORS
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
JP4495339B2 (en) * 1998-03-23 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド Piperidinyl and N-amidinopiperidinyl derivatives
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
US6297233B1 (en) 1999-02-09 2001-10-02 Bristol-Myers Squibb Company Lactam inhibitors of FXa and method
US6645968B2 (en) 1999-08-03 2003-11-11 Abbott Laboratories Potassium channel openers
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7225170B1 (en) 2000-07-27 2007-05-29 Pitney Bowes Inc. Postage metering system for use with business reply mail
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
CA2436774A1 (en) 2001-01-30 2002-08-08 R. Michael Lawrence Sulfonamide lactam inhibitors of factor xa
JP4101852B2 (en) 2004-05-26 2008-06-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 Cinnamide compounds
CA2580119A1 (en) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. Amorphous object of cinnamide compound
KR20080076907A (en) * 2005-11-18 2008-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 Process for production of cinnamamide derivative
US8354434B2 (en) 2006-01-30 2013-01-15 Purdue Pharma L.P. Cyclourea compounds as calcium channel blockers
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
CL2008000582A1 (en) 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd CYCLE COMPOUNDS DERIVED FROM CONDENSED OXIMORPHOLINE; PHARMACES THAT INCLUDE SUCH COMPOUNDS; AND ITS USE TO TREAT ALZHEIMER'S DISEASE, SENILE DEMENTIA, DOWN SYNDROME OR AMYLOIDOSIS.
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
TW200916469A (en) 2007-08-31 2009-04-16 Eisai R & Amp D Man Co Ltd Multi-cyclic compounds
EP2413701A4 (en) 2009-03-31 2012-10-03 Univ Vanderbilt Sulfonyl-azetidin-3-yl-methylamine amide analogs as glyt1 inhibitors, methods for making same, and use of same in treating psychiatric disorders

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372486A2 (en) * 1988-12-08 1990-06-13 F. Hoffmann-La Roche Ag Benzoic-acid phenylacetic-acid derivatives, their preparation and their use as medicines
EP0478328A1 (en) * 1990-09-27 1992-04-01 Merck & Co. Inc. Novel fibrinogen receptor antagonists
EP0478362A2 (en) * 1990-09-27 1992-04-01 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0512829A1 (en) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0512831A1 (en) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0540334A1 (en) * 1991-10-29 1993-05-05 Merck & Co. Inc. Fibrinogen receptor antagonists
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995025088A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridyl ethylation of lactam derivatives
WO1995025101A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridil ethylation of lactams
WO1996019221A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372486A2 (en) * 1988-12-08 1990-06-13 F. Hoffmann-La Roche Ag Benzoic-acid phenylacetic-acid derivatives, their preparation and their use as medicines
EP0478328A1 (en) * 1990-09-27 1992-04-01 Merck & Co. Inc. Novel fibrinogen receptor antagonists
EP0478362A2 (en) * 1990-09-27 1992-04-01 Merck & Co. Inc. Fibrinogen receptor antagonists
US5455243A (en) * 1991-05-07 1995-10-03 Merck & Co., Inc. Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets
EP0512829A1 (en) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0512831A1 (en) * 1991-05-07 1992-11-11 Merck & Co. Inc. Fibrinogen receptor antagonists
EP0540334A1 (en) * 1991-10-29 1993-05-05 Merck & Co. Inc. Fibrinogen receptor antagonists
WO1994008577A1 (en) * 1992-10-14 1994-04-28 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) * 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995017397A1 (en) * 1993-12-20 1995-06-29 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1995025088A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridyl ethylation of lactam derivatives
WO1995025101A1 (en) * 1994-03-14 1995-09-21 Merck & Co., Inc. Pyridil ethylation of lactams
WO1996019221A1 (en) * 1994-12-22 1996-06-27 Smithkline Beecham Corporation Fibrinogen receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9714417A1 *

Also Published As

Publication number Publication date
AU713247B2 (en) 1999-11-25
CA2234967A1 (en) 1997-04-24
WO1997014417A1 (en) 1997-04-24
EP0866705A1 (en) 1998-09-30
AU7432296A (en) 1997-05-07
JPH11513686A (en) 1999-11-24

Similar Documents

Publication Publication Date Title
EP0810994A4 (en) Fibrinogen receptor antagonists
EP0866705A4 (en) Fibrinogen receptor antagonists
EP0912175A4 (en) Fibrinogen receptor antagonists
HU9601529D0 (en) Pyrimidinedion-, pyrimidinetrion-, triazinedion-, tetrahydro-quinazolinedion- derivatives as alpha-adrenerg receptor antagonists
HU9603525D0 (en) Vironectin receptor antagonists
GB9405317D0 (en) Fibrinogen receptor antagonists
EP0819005A4 (en) 2-acylaminopropanamides as tachykinin receptor antagonists
AU1441695A (en) Fibrinogen receptor antagonists
AU3665793A (en) Fibrinogen receptor antagonists
EP0673247A4 (en) Fibrinogen receptor antagonists.
EP0667773A4 (en) Fibrinogen receptor antagonists.
HU9503402D0 (en) Neurokinin receptor antagonists
EP0885205A4 (en) Fibrinogen receptor antagonists
EP0885213A4 (en) Fibrinogen receptor antagonists
EP0796098A4 (en) Fibrinogen receptor antagonists
HU9601176D0 (en) Adhesion-receptor antagonists
HU9502028D0 (en) Fibrinogen receptor antagonists
EP0801650A4 (en) Fibrinogen receptor antagonists
AU5322994A (en) Fibrinogen receptor antagonists
ZA959434B (en) Adhesion receptor antagonists
EP0794779A4 (en) Fibrinogen receptor antagonists
GB9320799D0 (en) Fibrinogen receptor antagonists
GB9515852D0 (en) Fibrinogen receptor antagonists
EP0843551A4 (en) Endothelin receptor antagonists
HU9600333D0 (en) Adhesive receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980519

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched
AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20010417

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20011030